<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>生物科技股票在延長交易中出現劇烈波動，多個股票在常規交易大幅下跌後反彈。新的臨牀數據、FDA 的指定和融資公告推動了整個行業的動能，突顯出投資者密切關注的催化劑。</p>
<p>Stoke Therapeutics, Inc. (STOK) 在盤後交易中上漲至 $33.95 (+11.42%)，而常規交易收於 $30.47 (-7.67%)。此次反彈是在 2025 年 AES 年會上與 Biogen (BIIB) 的數據顯示，支持 zorevunersen 在 Dravet 綜合症中的潛力。</p>
<p>Alpha Tau Medical Ltd. (DRTS) 在盤後交易中股價大幅上漲。該股上漲至 $5.30，漲幅為 25.26%，即 $1.07。在常規市場收盤時（東部時間下午 4:00），股價為 $4.23，上漲 34 美分或 8.74%。該公司宣佈首位患者已在其針對複發性多形性膠質母細胞瘤（GBM）的試點研究中接受治療，使用 Alpha DaRT 技術。</p>
<p>Absci Corp. (ABSI) 在盤後交易中上漲至 $3.65 (+3.69%)，在常規交易收於 $3.52 (+2.03%)。週二沒有新的消息，但在 12 月 4 日，該公司宣佈在其 ABS-201 的 1/2a 階段 HEADLINE 研究中進行了首位志願者的給藥。</p>
<p>COMPASS Pathways plc (CMPS) 在盤後交易中上漲至 $6.64 (+4.40%)，而常規交易收於 $6.36 (+0.95%)。該公司宣佈計劃於 2026 年 1 月 7 日舉辦網絡研討會，討論 TRD 的商業準備和 PTSD 的臨牀試驗計劃。</p>
<p>Senti Biosciences, Inc. (SNTI) 在盤後交易中上漲至 $1.60 (+3.92%)，儘管常規交易大幅下跌至 $1.54 (-35.56%)。此次反彈是由於 FDA 授予 SENTI-202 其針對 AML 和其他血液惡性腫瘤的研究性 CAR-NK 細胞療法的 RMAT 指定。</p>
<p>TuHURA Biosciences, Inc. (HURA) 在盤後交易中小幅上漲至 $1.18 (+0.85%)，此前在收盤時大幅下跌至 $1.17 (-40.91%)。該公司宣佈以每股 $1.65 的價格直接發行 940 萬股股票和認股權證。</p>
<p>Maravai LifeSciences Holdings, Inc. (MRVI) 在盤後交易中上漲至 $3.86 (+7.32%)，而常規交易收於 $3.69 (+2.22%)。週二沒有報告公司特定的新聞。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

DRTS

CMPS

STOK

<p>生物科技股票在常規交易時段大幅下跌後，在盤後交易中反彈。Stoke Therapeutics、Alpha Tau Medical 和 Compass Pathways 領漲，得益於臨牀數據、FDA 認證和融資公告。Stoke Therapeutics 上漲 11.42%，Alpha Tau Medical 激增 25.26%，Compass Pathways 上漲 4.40%。其他值得注意的股票包括 Absci Corp、Senti Biosciences、TuHURA Biosciences 和 Maravai LifeSciences Holdings</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Biotech stocks showed sharp moves in extended trading, with several names rebounding after steep regular-session losses. Fresh clinical data, FDA designations, and financing announcements drove momentum across the sector, highlighting catalysts that investors are watching closely.</p>
<div class="lb-trans"><p>生物科技股票在延長交易中出現劇烈波動，多個股票在常規交易大幅下跌後反彈。新的臨牀數據、FDA 的指定和融資公告推動了整個行業的動能，突顯出投資者密切關注的催化劑。</p>
</div><p>Stoke Therapeutics, Inc. (STOK) traded up to $33.95 (+11.42%) post-market hours, after closing at $30.47 (-7.67%). The rebound followed data presentations with Biogen (BIIB) at the 2025 AES Annual Meeting, supporting the potential of zorevunersen for Dravet syndrome.</p>
<div class="lb-trans"><p>Stoke Therapeutics, Inc. (STOK) 在盤後交易中上漲至 $33.95 (+11.42%)，而常規交易收於 $30.47 (-7.67%)。此次反彈是在 2025 年 AES 年會上與 Biogen (BIIB) 的數據顯示，支持 zorevunersen 在 Dravet 綜合症中的潛力。</p>
</div><p>Alpha Tau Medical Ltd. (DRTS) saw a sharp surge in its share price during after-hours trading. The stock climbed to $5.30, marking a gain of 25.26%, or $1.07. At the regular market close, recorded at 4:00 PM EST, the shares settled at $4.23, up 34 cents or 8.74%. The company announced that the first patient has been treated in its pilot study for the treatment of patients with recurrent glioblastoma multiforme (GBM) using the Alpha DaRT technology.</p>
<div class="lb-trans"><p>Alpha Tau Medical Ltd. (DRTS) 在盤後交易中股價大幅上漲。該股上漲至 $5.30，漲幅為 25.26%，即 $1.07。在常規市場收盤時（東部時間下午 4:00），股價為 $4.23，上漲 34 美分或 8.74%。該公司宣佈首位患者已在其針對複發性多形性膠質母細胞瘤（GBM）的試點研究中接受治療，使用 Alpha DaRT 技術。</p>
</div><p>Absci Corp. (ABSI) rose to $3.65 (+3.69%) after hours, building on a close of $3.52 (+2.03%). No fresh news on Tuesday, but on December 4 the company announced first volunteer dosing in its Phase 1/2a HEADLINE study of ABS-201, an investigational anti-PRLR antibody.</p>
<div class="lb-trans"><p>Absci Corp. (ABSI) 在盤後交易中上漲至 $3.65 (+3.69%)，在常規交易收於 $3.52 (+2.03%)。週二沒有新的消息，但在 12 月 4 日，該公司宣佈在其 ABS-201 的 1/2a 階段 HEADLINE 研究中進行了首位志願者的給藥。</p>
</div><p>COMPASS Pathways plc (CMPS) climbed to $6.64 (+4.40%) after hours, after finishing at $6.36 (+0.95%). The company announced plans to host a webinar on Jan. 7, 2026, covering commercial preparations for TRD and clinical trial plans for PTSD.</p>
<div class="lb-trans"><p>COMPASS Pathways plc (CMPS) 在盤後交易中上漲至 $6.64 (+4.40%)，而常規交易收於 $6.36 (+0.95%)。該公司宣佈計劃於 2026 年 1 月 7 日舉辦網絡研討會，討論 TRD 的商業準備和 PTSD 的臨牀試驗計劃。</p>
</div><p>Senti Biosciences, Inc. (SNTI) surged to $1.60 (+3.92%) after hours, despite closing sharply lower at $1.54 (-35.56%). The rally was driven by news that the FDA granted RMAT designation to SENTI-202, its investigational CAR-NK cell therapy for AML and other hematologic malignancies.</p>
<div class="lb-trans"><p>Senti Biosciences, Inc. (SNTI) 在盤後交易中上漲至 $1.60 (+3.92%)，儘管常規交易大幅下跌至 $1.54 (-35.56%)。此次反彈是由於 FDA 授予 SENTI-202 其針對 AML 和其他血液惡性腫瘤的研究性 CAR-NK 細胞療法的 RMAT 指定。</p>
</div><p>TuHURA Biosciences, Inc. (HURA) edged up to $1.18 (+0.85%) after hours, following a steep decline to $1.17 (-40.91%) at the close. The company announced a registered direct offering of 9.4 million shares and warrants, priced at $1.65 per share.</p>
<div class="lb-trans"><p>TuHURA Biosciences, Inc. (HURA) 在盤後交易中小幅上漲至 $1.18 (+0.85%)，此前在收盤時大幅下跌至 $1.17 (-40.91%)。該公司宣佈以每股 $1.65 的價格直接發行 940 萬股股票和認股權證。</p>
</div><p>Maravai LifeSciences Holdings, Inc. (MRVI) advanced to $3.86 (+7.32%) after hours, after closing at $3.69 (+2.22%). No company-specific news was reported on Tuesday.</p>
<div class="lb-trans"><p>Maravai LifeSciences Holdings, Inc. (MRVI) 在盤後交易中上漲至 $3.86 (+7.32%)，而常規交易收於 $3.69 (+2.22%)。週二沒有報告公司特定的新聞。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

盤後股價上漲：Stoke Therapeutics、Alpha Tau Medical、Compass Pathways 領漲生物科技股